SPORE IN BREAST CANCER

我们在这里提出一个专门的乳房卓越研究项目 满足肿瘤界对肿瘤综合治疗的需求 临床和实验室致力于减少 以及乳腺癌的死亡率。孢子将由一个 主任1名科学协调员、一个指导委员会、5名主要 研究项目，两个核心资源(行政和病理学)， 发展研究计划和职业发展计划。 这些项目将包括对erbB-2、erbB-3和erbB-4的研究， 谷氨酰转氨酶、表皮生长因子受体、ras和法尼基蛋白转移酶抑制物，TC- 21，转化生长因子-β，代表性差异分析，敏感性 基因(BRCA1)、细胞周期蛋白和p53。这些实验室调查将 转化为对病因、诊断、分期、 预后、治疗反应和生活质量。方向盘 委员会将由主任(诺顿博士)、科学部 协调员(N·罗森博士)，乳腺病理核心负责人 资源(P.P.罗森博士)，五个主要项目的负责人 (Aaronson博士，Massague博士，Mendelsohn博士，N.Rosen博士，Wigler博士)，Lucio博士 卢扎托(人类遗传学)、贝格博士(生物统计学)、劳埃德·奥尔德博士 (免疫学)，Borgen博士(外科)，Beryl McCormick博士(放射 和艾米·兰格女士(全国联盟执行主任 乳腺癌组织的成员)。加速改良的孢子 网络，我们倡导并将组织频繁的会议 被资助的孢子的董事。我们还提议协调 我们与各NCI代表的活动- 除孢子外的赞助组织资源库/登记处，以及 与协作组乳腺癌委员会的主席。我们 设计了丰富的组织资源，对我们的孢子有价值 以及我们计划组织的更广泛的网络。监督将是 由MSKCC委员会和著名的科学顾问委员会。

We here propose a Specialized Program of Research Excellence in Breast Cancer to meet the needs of the oncologic community for an integrated clinical and laboratory effort dedicated to reducing the incidence of and mortality from breast cancer. The SPORE will be composed of one Director one Scientific Coordinator, a Steering Committee, five main research projects, two core resources (Administrative and Pathology), a Developmental Research Program, and a Career Development Program. The projects will include studies of erbB-2, erbB-3, and erbB-4, heregulin, EGFR, ras and farnesyl protein transferase inhibitors, TC- 21, TGF-beta, representational difference analysis, susceptibility genes (BRCA1), cyclins, and p53. These laboratory investigations will translate into a better understanding of etiology, diagnosis, staging, prognosis, therapeutic response, and quality-of-life. The Steering Committee will consist of the Director (Dr. Norton), the Scientific Coordinator (Dr. N. Rosen), the Head of the Breast Pathology Core Resource (Dr. P. P. Rosen), the leaders of the five main projects (Drs. Aaronson, Massague, Mendelsohn, N. Rosen, Wigler), Dr. Lucio Luzzatto (Human Genetics), Dr. Begg (Biostatistics), Dr. Lloyd Old (Immunology), Dr. Borgen (Surgery), Dr. Beryl McCormick (Radiation Therapy), and Ms. Amy Langer (Executive Director, National Alliance of Breast Cancer Organizations). To expedite an improved SPORE network, we advocate and will organize frequent meetings of the Directors of the funded SPOREs. We would also propose to coordinate our activities with those of representatives of the various NCI- sponsored tissue resource banks/registries other than the SPOREs, and with the chairs of the Cooperative Group Breast Cancer Committees. We have designed an extensive tissue resource to be of value to our SPORE and to the wider network that -we plan to organize. Oversight will be by MSKCC committees and by an eminent Board of Scientific Advisors.